What Researchers Did
Researchers conducted a phase 1 dose-escalation study to assess the feasibility of hyperbaric oxygen (HBO) treatments immediately before intensity-modulated radiation therapy and cisplatin chemotherapy for locally advanced squamous cell carcinoma of the head and neck.
What They Found
Twelve patients with locally advanced squamous cell carcinoma of the oropharynx were enrolled in this study. No dose-limiting toxicities were observed with daily hyperbaric oxygen treatments, though two patients (22%) required pressure equalization tubes. The average time between hyperbaric oxygen and radiation therapy was 8.5 minutes.
What This Means for Canadian Patients
This study suggests that hyperbaric oxygen therapy immediately before radiation and chemotherapy for head and neck cancer may be feasible and well-tolerated. If further research confirms its efficacy, this approach could potentially improve treatment outcomes for Canadian patients with locally advanced squamous cell carcinoma of the oropharynx.
Canadian Relevance
This study was not conducted in Canada and does not have a direct Canadian connection.
Study Limitations
A primary limitation of this study is its small sample size of 12 patients, characteristic of a phase 1 dose-escalation design focused on feasibility rather than efficacy.